Fletikumab
- Generic Name
- Fletikumab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1357158-22-5
- Unique Ingredient Identifier
- 82WG3POL9W
- Background
Fletikumab is under investigation in clinical trial NCT01038674 (Safety and Tolerability of Anti-IL-20 in Subjects With Rheumatoid Arthritis).
- Associated Conditions
- -
- Associated Therapies
- -
First Human Dose Study of Anti-IL-20 in Psoriasis: A Study of Safety, Tolerability and Early Signals of Biologic and Clinical Effects
- First Posted Date
- 2010-12-16
- Last Posted Date
- 2017-02-09
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 55
- Registration Number
- NCT01261767
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Norfolk, Virginia, United States
Safety and Tolerability of Anti-IL-20 in Subjects With Rheumatoid Arthritis
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-12-24
- Last Posted Date
- 2017-02-09
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 16
- Registration Number
- NCT01038674
- Locations
- 🇵🇱
Novo Nordisk Investigational Site, Warszawa, Poland
Safety and Tolerability of Anti-IL-20 in Healthy Volunteers and Patients With Rheumatoid Arthritis
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-01-07
- Last Posted Date
- 2017-02-09
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 32
- Registration Number
- NCT00818064
- Locations
- 🇳🇱
Novo Nordisk Investigational Site, Groningen, Netherlands
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath